Complement C5 inhibition in patients with COVID-19 - a promising target?

Título

Complement C5 inhibition in patients with COVID-19 - a promising target?

Autor

Regis Peffault de Latour, Anne Bergeron, Etienne Lengline, Thibault Dupont, Armance Marchal, Lionel Galicier, Nathalie de Castro, Louise Bondeelle, Michael Darmon, Clairelyne Dupin, Guillaume Dumas, Pierre Leguen, Isabelle Madelaine, Sylvie Chevret, Jean-Michel Molina, Elie Azoulay, Veronique Fremeaux-Bacchi, Core Group

Fecha

2020

Identificador

10.3324/haematol.2020.260117

Fuente

Haematologica

Archivos

https://socictopen.socict.org/files/to_import/pdfs/24e889e0271a6209a6cb77402b33c88a.pdf

Colección

Coronavirus

Citación

Regis Peffault de Latour, Anne Bergeron, Etienne Lengline, Thibault Dupont, Armance Marchal, Lionel Galicier, Nathalie de Castro, Louise Bondeelle, Michael Darmon, Clairelyne Dupin, Guillaume Dumas, Pierre Leguen, Isabelle Madelaine, Sylvie Chevret, Jean-Michel Molina, Elie Azoulay, Veronique Fremeaux-Bacchi, Core Group, “Complement C5 inhibition in patients with COVID-19 - a promising target?,” SOCICT Open, consulta 20 de abril de 2026, https://socictopen.socict.org/items/show/8253.

Formatos de Salida

Position: 16098 (19 views)